Comparing the Top Two: Lumentum Holdings Inc. (NASDAQ:LITE), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Lumentum Holdings Inc. (NASDAQ:LITE)

Lumentum Holdings Inc. (NASDAQ:LITE) closed at $60.75 on the last trading session with an increase of 1.01%, whereas, it previously closed at $60.14. The company has a market capitalization of $4.58 Billion. The company traded shares of 1.14 Million on the trading day while its three month average volume stands at 1.68 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Lumentum Holdings Inc. (NASDAQ:LITE) produced diluted EPS of 1.47. The EPS estimate for next year as estimated by analysts is at 5.13 while EPS for next quarter is estimated at 0.85. Earnings per Share growth for this year is reported at 398.1, while the analysts estimated the EPS growth for next year at 5.13% and Earnings growth for next 5 years stands at 12% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 105.5%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Lumentum Holdings Inc. (NASDAQ:LITE) is at 41.35 while the forward p/e is at 11.84. The P/S or Price to Sales ratio of Lumentum Holdings Inc. (NASDAQ:LITE) stands at 3.45 and Price to Book or P/B for the most recent quarter stands at 2.6. The Price to Free Cash Flow ratio or P/FCF is reported at 18.41. The quick ratio and the current ratio of Lumentum Holdings Inc. (NASDAQ:LITE) are reported at 3.2 and 4.2 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Lumentum Holdings Inc. (NASDAQ:LITE) stands at 5.2, 8.9 and 26.7 respectively

The trailing twelve month Revenue of Lumentum Holdings Inc. (NASDAQ:LITE) is reported at 1.33 Billion with income of 94.6 Million. The outstanding shares of Lumentum Holdings Inc. (NASDAQ:LITE) are 75.34 Million. The institutional Ownership of the shares of 87.5 stands at 0.80%, this figure is increased 0.91 in the last six months. The insider ownership for the shares of Lumentum Holdings Inc. (NASDAQ:LITE) is ticked at 1%, the figure is plummeted -2.18% in the last six months.

Some other important financial aspects to be discussed here for Lumentum Holdings Inc. (NASDAQ:LITE) is the Mean Target Price estimated by the analysts which stands at 67.27. The 52 week high of Lumentum Holdings Inc. (NASDAQ:LITE) is placed at 69.95 and 52 week low is standing at 37.00.

Performance wise the shares of Lumentum Holdings Inc. (NASDAQ:LITE) rose up 3.16% for the week, it also rise 22.33% for the monthly performance, while for the quarter it went down 32.07%. The shares decrease -1.91% for the half year and flew up for the Year-To-Date performance. The shares of Lumentum Holdings Inc. (NASDAQ:LITE) shrinked -3.65% for the yearly performance.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) closed at $6.31 on the last trading session with an decrease of -0.16%, whereas, it previously closed at $6.32. The company has a market capitalization of $538.51 Million. The company traded shares of 438625 on the trading day while its three month average volume stands at 881.51 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) produced diluted EPS of -0.76. The EPS estimate for next year as estimated by analysts is at -0.55 while EPS for next quarter is estimated at -0.15. Earnings per Share growth for this year is reported at -54.5, while the analysts estimated the EPS growth for next year at -0.55% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 0%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) stands at 1163.1 and Price to Book or P/B for the most recent quarter stands at 4.79. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) are reported at 0 and 0 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) stands at 0, 0 and 0 respectively

The trailing twelve month Revenue of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is reported at 460000 with income of 0. The outstanding shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) are 85.34 Million. The institutional Ownership of the shares of 0 stands at 0.80%, this figure is increased 0 in the last six months. The insider ownership for the shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is ticked at 0%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is the Mean Target Price estimated by the analysts which stands at 11.92. The 52 week high of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is placed at 7.85 and 52 week low is standing at 5.06.

Performance wise the shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) fell down -3.81% for the week, it also fell -7.61% for the monthly performance, while for the quarter it went up -15.19%. The shares increase 6.05% for the half year and plummeted for the Year-To-Date performance. The shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) grew 12.88% for the yearly performance.